---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-25-000111"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T04:26:31.969851+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pfizer Q1 revenues $13.7B (-8% YoY), adjusted EPS $0.92 (+12%); reaffirms FY2025 guidance

## Summary
- Q1 revenues $13.7B, down 8% YoY; reported diluted EPS $0.52 (down 5%), adjusted diluted EPS $0.92 (up 12%).
- Reaffirms FY2025 guidance: revenue $61-$64B, adjusted diluted EPS $2.80-$3.00, with no share buybacks anticipated.
- Expands cost realignment: additional $1.2B net savings by 2027 (SI&A focus) plus $500M R&D reinvestment by 2026; one-time costs $1.6B and $600M respectively.
- Paxlovid revenue fell $1.5B operationally (75% drop); Vyndaqel family grew 33% operationally; Comirnaty up 62% operationally.
- Paid $2.4B in cash dividends ($0.43/shr) in Q1; gross leverage below previously stated target; $3.3B remaining buyback authority.

## SEC filing metadata
- accession: 0000078003-25-000111
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800325000111/0000078003-25-000111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800325000111/pfe-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-25-000111
- JSON: https://secwatch.observer/filing/0000078003-25-000111.json
- Plain text: https://secwatch.observer/filing/0000078003-25-000111.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.